Parkinson’s Disease Therapeutics Market Briefing and Future Outlook 2021 to 2027

The Parkinson’s disease therapeutics market expansion would be augmented by extensive investments in R&D activities to uplift the development in the treatment of the disease. Reportedly, the Parkinson’s Foundation in 2020 invested nearly US$3.5 million in 34 research programs to support the efforts of promising scientists in the field of Parkinson’s disease (PD).

Growing funding in clinical research and development activities is projected to push the Parkinson’s disease therapeutics market growth over time. Lack of knowledge and awareness among people regarding Parkinson’s disease can potentially cause an increase in patient count. The unawareness posed barriers to early diagnosis and provision of optimal care to affected patients has led to the commencement of many awareness programs.

Get sample copy of this research report @ https://www.decresearch.com/request-sample/detail/2724

The Parkinson’s disease therapeutics market progression would further be augmented by the growing awareness among the population about the disease. Early diagnosis of the disease plays a key role in providing effective treatment to the affected patient. The lack of awareness and knowledge among people about Parkinson’s disease has led to the commencement of numerous awareness programs. For instance, World Parkinson’s Day is an initiative to encourage new research and treatment programs by creating awareness among the population pertaining to the disease.

The dopamine agonists segment accounted for a considerable revenue share at nearly US$694 million in 2020. The medication is highly preferred in the treatment of Parkinson’s disease owing to its resemblance to the effect of dopamine in the brain. The medication does not contain any side effects such as dyskinesia, which is mostly caused by other drugs. These drugs are adopted to improve the condition-related symptoms by indicating the presence of dopamine in the brain, therefore propelling industry growth.

The adult patient segment of the Parkinson’s disease therapeutics market is expected to grow at 6.9% CAGR up to 2027. The segment expansion is majorly attributed to the growing vulnerability to idiopathic Parkinson’s disease among the aging population base. The rapidly growing aging population base across the globe has resulted in a large number of patients being affected by Parkinson’s disease.

The Parkinson’s disease therapeutics market of Brazil accounted for the highest market share in the year 2020. Brazil was the highest shareholder due to growing cases of Parkinson’s disease in the region, and substantial fiscal & infrastructure expansion in the country. Brazil has a unique research sector in biotechnology and pharmacology which is always supported by a defined government for focusing on various diseases. Reports state that the Brazil Parkinson’s disease therapeutic industry was valued at more than USD 90 million in 2020.

Key players and competitors operating in this niche are constantly focusing on strategic acquisitions to support new product launches, capture more market share and strengthen revenue generation.

Some of these firms include UCB, Orion Corporation, Acadia Pharmaceuticals, Amneal Pharmaceuticals, Roche, AbbVie Inc., Teva Pharmaceutical among others. These players have executed several strategic initiatives and innovative product launches to maintain a competitive edge in the Parkinson’s disease therapeutics market.

Request for a Customization of this research report @ https://www.decresearch.com/roc/2724

Partial Chapter of the Table of Content

Chapter 4   Parkinson’s Disease Therapeutics Market, By Drug Class

4.1    Key segment trends

4.2    Levodopa/Carbidopa

4.2.1    Market size, by region, 2016 - 2027 (USD Million)

4.3    Dopamine Agonist

4.3.1    Market size, by region, 2016 - 2027 (USD Million)

4.4    Adenosine A2A Antagonist

4.4.1    Market size, by region, 2016 - 2027 (USD Million)

4.5    COMT Inhibitors

4.5.1    Market size, by region, 2016 - 2027 (USD Million)

4.6    MAO-B Inhibitors

4.6.1    Market size, by region, 2016 - 2027 (USD Million)

4.7    Glutamate Antagonist

4.7.1    Market size, by region, 2016 - 2027 (USD Million)

4.8    Others

4.8.1    Market size, by region, 2016 - 2027 (USD Million)

Chapter 5   Parkinson’s Disease Therapeutics Market, By Route of Administration

5.1    Key segment trends

5.2    Oral

5.2.1    Market size, by region, 2016 - 2027 (USD Million)

5.3    Subcutaneous

5.3.1    Market size, by region, 2016 - 2027 (USD Million)

5.4    Transdermal

5.4.1    Market size, by region, 2016 - 2027 (USD Million)

5.5    Others

5.5.1    Market size, by region, 2016 - 2027 (USD Million)

Chapter 6   Parkinson’s Disease Therapeutics Market, By Patient

6.1    Key segment trends

6.2    Adult

6.2.1    Market size, by region, 2016 - 2027 (USD Million)

6.3    Pediatric

6.3.1    Market size, by region, 2016 - 2027 (USD Million)

Browse complete Table of Contents (ToC) of this research report @ https://www.decresearch.com/toc/detail/parkinsons-disease-therapeutics-market